person · Reporting owner

CHAUDHURI BHASKAR

Disclosed activity across 4 companies

Tapewire entity: 34849
SEC CIK: 0001458643

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Arcutis Biotherapeutics, Inc.ARQT · Entity 4236	Director	June 12, 2025	June 17, 2025
Tarsus Pharmaceuticals, Inc.TARS · Entity 1836	Director	June 25, 2026	June 29, 2026
Teligent, Inc.TLGT · Entity 134764	Director	January 04, 2021	January 06, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcutis Biotherapeutics, Inc.

Report date June 12, 2025 · Filed June 17, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	867,826	Reported balance After 2025-06-12 transaction · row 1 1 source row Row 1 · 2025-06-12 · Grant · Acquired 7,609 · Balance 867,826 F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 11, 2024, maintained by the Company.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.50 · Expires 2035-06-12	Direct	20,568	Reported balance After 2025-06-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-06-12 · Grant · Acquired 20,568 · Balance 20,568 F3: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
Common StockSEC Table I · non-derivative	IndirectBy Trust	49,981	Reported balance Holding disclosure · report date 2025-06-12 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 49,981 F2: The securities are held of record by The Chaudhuri Family Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 11, 2024, maintained by the Company.

F2: The securities are held of record by The Chaudhuri Family Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

F3: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Tarsus Pharmaceuticals, Inc.

Report date June 25, 2026 · Filed June 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.34 · Expires 2036-06-24	Direct	3,837	Reported balance After 2026-06-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-25 · Grant · Acquired 3,837 · Balance 3,837 F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,417	Reported balance After 2026-06-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-25 · Grant · Acquired 2,417 · Balance 2,417 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Filing footnotes · ownership attribution and instrument terms

F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Teligent, Inc.

Report date January 04, 2021 · Filed January 06, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2031-01-04	Direct	2,000	Reported balance After 2021-01-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-01-04 · Grant · Acquired 2,000 · Balance 2,000 F2: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1: These securities shall vest fully 12 months from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: These securities shall vest fully 12 months from the date of grant.

F2: These securities were granted as part of the Issuer's equity compensation to its non-employee directors.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Corium International, Inc.

Report date November 27, 2018 · Filed November 29, 2018

Section 16 reporting ended · disclosed 2018-11-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2023-02-27	Direct	Reported balance After 2018-11-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-11-27 · Disposition to issuer · Disposed 34,203 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2024-01-25	Direct	Reported balance After 2018-11-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-11-27 · Disposition to issuer · Disposed 7,920 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.79 · Expires 2024-12-03	Direct	Reported balance After 2018-11-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.19 · Expires 2025-12-17	Direct	Reported balance After 2018-11-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2026-12-21	Direct	Reported balance After 2018-11-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2027-11-30	Direct	Reported balance After 2018-11-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").

F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 25, 2026 Filed Jun 29, 2026 20:31 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantRestricted Stock Units · Derivative	2,417	$0.00	$0.00	Disclosure SEC source: 0001458643-26-000004 · wk-form4_1782765084.xml · derivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,417 Underlying: Common Stock · 2,417 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 25, 2026 Filed Jun 29, 2026 20:31 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantStock Option (right to buy) · Derivative	3,837	$0.00 Strike: $64.34	$0.00	Disclosure SEC source: 0001458643-26-000004 · wk-form4_1782765084.xml · derivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,837 Underlying: Common Stock · 3,837 shares Expires 2036-06-24 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 12, 2026 Filed Jun 16, 2026 20:06 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	Exercise / conversionRestricted Stock Units · Derivative	2,954	$0.00	$0.00	Disclosure SEC source: 0001458643-26-000002 · wk-form4_1781640370.xml · derivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 12, 2026 Filed Jun 16, 2026 20:06 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	Exercise / conversionCommon Stock	2,954	Not disclosed	Not disclosed	Disclosure SEC source: 0001458643-26-000002 · wk-form4_1781640370.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document
June 13, 2025 Filed Jun 16, 2025 20:05 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	Exercise / conversionRestricted Stock Units · Derivative	3,350	$0.00	$0.00	Disclosure SEC source: 0001819790-25-000094 · wk-form4_1750104325.xml · derivative · entry 4 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F5 · derivative.expiration_date: RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 13, 2025 Filed Jun 16, 2025 20:05 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	Exercise / conversionCommon Stock	3,350	Not disclosed	Not disclosed	Disclosure SEC source: 0001819790-25-000094 · wk-form4_1750104325.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:05 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantRestricted Stock Units · Derivative	2,954	$0.00	$0.00	Disclosure SEC source: 0001819790-25-000094 · wk-form4_1750104325.xml · derivative · entry 3 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,954 Underlying: Common Stock · 2,954 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F4 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 12, 2025 Filed Jun 16, 2025 20:05 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantStock Option (right to buy) · Derivative	4,540	$0.00 Strike: $40.95	$0.00	Disclosure SEC source: 0001819790-25-000094 · wk-form4_1750104325.xml · derivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,540 Underlying: Common Stock · 4,540 shares Expires 2035-06-11 F2 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 12, 2025 Filed Jun 17, 2025 00:16 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (right to buy) · Derivative	20,568	$0.00 Strike: $13.50	$0.00	Disclosure SEC source: 0002065881-25-000022 · wk-form4_1750119408.xml · derivative · entry 3 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,568 Underlying: Common Stock · 20,568 shares Expires 2035-06-12 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document
June 12, 2025 Filed Jun 17, 2025 00:16 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantCommon Stock	7,609	$0.00	$0.00	Disclosure SEC source: 0002065881-25-000022 · wk-form4_1750119408.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 867,826 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on December 11, 2024, maintained by the Company. Read SEC document
June 24, 2024 Filed Jun 25, 2024 22:22 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	Exercise / conversionRestricted Stock Units · Derivative	3,350	$0.00	$0.00	Disclosure SEC source: 0001819790-24-000098 · wk-form4_1719354137.xml · derivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 24, 2024 Filed Jun 25, 2024 22:22 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	Exercise / conversionCommon Stock	3,350	Not disclosed	Not disclosed	Disclosure SEC source: 0001819790-24-000098 · wk-form4_1719354137.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document
June 14, 2024 Filed Jun 18, 2024 20:51 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (right to buy) · Derivative	27,052	$0.00 Strike: $8.63	$0.00	Disclosure SEC source: 0001787306-24-000099 · wk-form4_1718743875.xml · derivative · entry 3 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,052 Underlying: Common Stock · 27,052 shares Expires 2034-06-14 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document
June 14, 2024 Filed Jun 18, 2024 20:51 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantCommon Stock	10,139	$0.00	$0.00	Disclosure SEC source: 0001787306-24-000099 · wk-form4_1718743875.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 860,217 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 13, 2024 Filed Jun 14, 2024 21:44 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantRestricted Stock Units · Derivative	3,350	$0.00	$0.00	Disclosure SEC source: 0001819790-24-000083 · wk-form4_1718401434.xml · derivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 13, 2024 Filed Jun 14, 2024 21:44 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $33.14	$0.00	Disclosure SEC source: 0001819790-24-000083 · wk-form4_1718401434.xml · derivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 22, 2023 Filed Jun 26, 2023 21:58 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantRestricted Stock Units · Derivative	3,350	$0.00	$0.00	Disclosure SEC source: 0001819790-23-000060 · wk-form4_1687816717.xml · derivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 22, 2023 Filed Jun 26, 2023 21:58 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $17.99	$0.00	Disclosure SEC source: 0001819790-23-000060 · wk-form4_1687816717.xml · derivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 16, 2023 Filed Jun 21, 2023 22:25 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	Exercise / conversionRestricted Stock Units · Derivative	2,000	$0.00	$0.00	Disclosure SEC source: 0001819790-23-000045 · wk-form4_1687386330.xml · derivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 16, 2022, in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 16, 2022, in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 16, 2023 Filed Jun 21, 2023 22:25 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	Exercise / conversionCommon Stock	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001819790-23-000045 · wk-form4_1687386330.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document
May 31, 2023 Filed Jun 2, 2023 23:13 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (right to buy) · Derivative	12,220	$0.00 Strike: $7.51	$0.00	Disclosure SEC source: 0001787306-23-000060 · wk-form4_1685747612.xml · derivative · entry 3 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,220 Underlying: Common Stock · 12,220 shares Expires 2033-05-31 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023. Read SEC document
May 31, 2023 Filed Jun 2, 2023 23:13 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantCommon Stock	4,375	$0.00	$0.00	Disclosure SEC source: 0001787306-23-000060 · wk-form4_1685747612.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,078 F1 · balance_after: Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document
June 16, 2022 Filed Jul 1, 2022 16:30 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantRestricted Stock Units · Derivative	2,000	$0.00	$0.00	Disclosure SEC source: 0001628280-22-018347 · wf-form4_165669302435061.xml · derivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 16, 2022 Filed Jul 1, 2022 16:30 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantStock Option (right to buy) · Derivative	7,000	$0.00 Strike: $12.89	$0.00	Disclosure SEC source: 0001628280-22-018347 · wf-form4_165669302435061.xml · derivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2022 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 01, 2022 Filed Jun 3, 2022 20:57 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (Right to Buy) · Derivative	11,796	$0.00 Strike: $20.29	$0.00	Disclosure SEC source: 0001567619-22-012321 · doc1.xml · derivative · entry 3 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,796 Underlying: Common Stock · 11,796 shares Expires 2032-06-01 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022. Read SEC document
June 01, 2022 Filed Jun 3, 2022 20:57 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantCommon Stock	4,312	$0.00	$0.00	Disclosure SEC source: 0001567619-22-012321 · doc1.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,703 F1 · balance_after: Includes 4,312 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document
June 25, 2021 Filed Jun 28, 2021 20:11 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	6,755	$27.50	$185,762.50	Disclosure SEC source: 0001567619-21-012655 · doc1.xml · nonDerivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 841,391 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
June 24, 2021 Filed Jun 28, 2021 20:11 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	729	$27.50	$20,047.50	Disclosure SEC source: 0001567619-21-012655 · doc1.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,146 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
June 21, 2021 Filed Jun 23, 2021 21:47 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	2,516	$27.50	$69,190.00	Disclosure SEC source: 0001567619-21-012548 · doc1.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,875 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
June 15, 2021 Filed Jun 17, 2021 23:20 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $35.26	$0.00	Disclosure SEC source: 0001209191-21-041702 · doc4.xml · derivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-15 F2 · derivative.exercise_date: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested. Read SEC document
June 15, 2021 Filed Jun 17, 2021 23:20 UTC	Tarsus Pharmaceuticals, Inc. TARS · Entity 1836	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $35.26	$0.00	Disclosure SEC source: 0001209191-21-041702 · doc4.xml · derivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document
June 09, 2021 Filed Jun 11, 2021 20:34 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (Right to Buy) · Derivative	13,391	$0.00 Strike: $27.77	$0.00	Disclosure SEC source: 0001567619-21-012024 · doc1.xml · derivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,391 Underlying: Common Stock · 13,391 shares Expires 2031-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of (i) the first anniversary of June 9, 2021 or (ii) the next Annual Meeting following June 9, 2021, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document
June 01, 2021 Filed Jun 3, 2021 20:39 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	10,000	$27.50	$275,000.00	Disclosure SEC source: 0001567619-21-011610 · doc1.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,391 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
April 20, 2021 Filed Apr 23, 2021 00:17 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	1,280	$28.53	$36,515.46	Disclosure SEC source: 0001567619-21-008502 · doc1.xml · nonDerivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 861,391 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $28.50 to $28.73, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
April 20, 2021 Filed Apr 23, 2021 00:17 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	8,720	$27.99	$244,052.74	Disclosure SEC source: 0001567619-21-008502 · doc1.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 862,671 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $27.50 to $28.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
April 20, 2021 Filed May 19, 2021 22:43 UTC Amendment	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	1,280	$28.53	$36,515.46	Disclosure SEC source: 0001567619-21-010739 · doc1.xml · nonDerivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 861,391 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $28.50 to $28.73, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5 · balance_after: The Form 4/A filed by the Reporting Person on 5/12/2021 was filed in error. The original Form 4 filed by the Reporting Person on 04/22/2021 accurately reported the transactions as they occurred. This Form 4/A corrects the aforementioned error by restating the original Form 4 in its entirety. Read SEC document
April 20, 2021 Filed May 19, 2021 22:43 UTC Amendment	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	8,720	$27.99	$244,052.74	Disclosure SEC source: 0001567619-21-010739 · doc1.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 862,671 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $27.50 to $28.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5 · balance_after: The Form 4/A filed by the Reporting Person on 5/12/2021 was filed in error. The original Form 4 filed by the Reporting Person on 04/22/2021 accurately reported the transactions as they occurred. This Form 4/A corrects the aforementioned error by restating the original Form 4 in its entirety. Read SEC document
March 22, 2021 Filed Mar 24, 2021 15:33 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	4,992	$31.43	$156,905.55	Disclosure SEC source: 0001567619-21-006825 · doc1.xml · nonDerivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871,391 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $31.24 to $31.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
March 22, 2021 Filed Mar 24, 2021 15:33 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	5,008	$30.77	$154,115.19	Disclosure SEC source: 0001567619-21-006825 · doc1.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 876,383 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $30.20 to $31.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
February 22, 2021 Filed Feb 24, 2021 20:33 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	2,789	$35.97	$100,325.35	Disclosure SEC source: 0001567619-21-004762 · doc1.xml · nonDerivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,391 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $35.80 to $36.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
February 22, 2021 Filed Feb 24, 2021 20:33 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	7,211	$35.34	$254,865.58	Disclosure SEC source: 0001567619-21-004762 · doc1.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,180 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $34.80 to $35.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
February 01, 2021 Filed Feb 3, 2021 00:39 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	9,949	$33.25	$330,804.25	Disclosure SEC source: 0001567619-21-002041 · doc1.xml · nonDerivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891,391 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
January 29, 2021 Filed Feb 3, 2021 00:39 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	SaleCommon Stock	51	$27.50	$1,402.50	Disclosure SEC source: 0001567619-21-002041 · doc1.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,340 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
January 04, 2021 Filed Jan 6, 2021 11:00 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	2,000	$0.00 Strike: $0.74	$0.00	Disclosure SEC source: 0000352998-21-000003 · primary_doc.xml · derivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2031-01-04 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document
February 27, 2020 Filed Mar 4, 2020 01:57 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $27.61	$0.00	Disclosure SEC source: 0001567619-20-005543 · doc1.xml · derivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests and becomes exercisable 100% on the earlier of the date of the next annual meeting of the Issuer's stockholders or February 27, 2021. Read SEC document
February 04, 2020 Filed Feb 4, 2020 23:26 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	ConversionSeries A Preferred Stock · Derivative	49,981	$0.00	$0.00	Disclosure SEC source: 0001209191-20-006599 · doc4.xml · derivative · entry 4 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 49,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The securities are held of record by The Chaudhuri Family Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
February 04, 2020 Filed Feb 4, 2020 23:26 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	ConversionSeries A Preferred Stock · Derivative	37,486	$0.00	$0.00	Disclosure SEC source: 0001209191-20-006599 · doc4.xml · derivative · entry 3 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,486 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document
February 04, 2020 Filed Feb 4, 2020 23:26 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	ConversionCommon Stock	49,981	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-006599 · doc4.xml · nonDerivative · entry 2 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 49,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The securities are held of record by The Chaudhuri Family Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
February 04, 2020 Filed Feb 4, 2020 23:26 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	ConversionCommon Stock	37,486	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-006599 · doc4.xml · nonDerivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. Read SEC document
January 02, 2020 Filed Jan 3, 2020 10:50 UTC	Teligent, Inc. TLGT · Entity 134764	GrantStock Option · Derivative	20,000	$0.00 Strike: $0.42	$0.00	Disclosure SEC source: 0001104659-20-000632 · tm201128d2_4.xml · derivative · entry 1 CHAUDHURI BHASKAR · CIK 0001458643 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-02 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.